Predicting anthracycline benefit: Have we made any progress?

Current Opinion in Oncology

Volumn 21, Issue 6, 2009, Pages 507-515

  Moretti, Erica ^a   Oakman, Catherine ^a   Di Leo, Angelo ^a  

^a HOSPITAL OF PRATO   (Italy)

Author keywords

Anthracycline; Biomarker; Breast cancer; HER 2; Topoisomerase ii

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BIOLOGICAL MARKER; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRASTUZUMAB; VINBLASTINE; ANTHRACYCLINE; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHROMOSOME 17; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EARLY CANCER; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FEMALE; METABOLISM; PREDICTION AND FORECASTING;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 74049111479     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328331a501     Document Type: Review

References (67)

1. Early Breast Cancer Trialists' Collaborative Group: multiagent chemotherapy for early breast cancer. Cochrane Database Syst Rev 1 :CD000487, 2002.
2. DeVita V, Lawrence T, Rosenberg S. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008.
3. Treszezamsky AD, Kachnic LA, Feng Z, et al. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 2007; 67:7078-7081. (Pubitemid 47206532)
4. Sauter G, Lee J, Bartlett J, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin One 2009; 8:1323-1333.
5. Wolff A, Hammond M, Schwartz, et al. American Society of Clinical Oncology/ College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing In Breast Cancer. J Clin One 2007; 1:118-145. (Pubitemid 350003059)
6. Miller DV, Jenkins RB, Lingle WL, et al. Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 lntergroup Adjuvant Trial. Proc Am Soc Clin Oncol 2004; 568 [abstract].
7. Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin In patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90:1361-1370. (Pubitemid 28439960)
8. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92:1991-1998. (Pubitemid 32045895)
9. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8:1483-1496.
10. De Laurentiis M, Caputo F, Massarelli E, et al. HER2 expression and anthracycline effect: results from the Naples GUN3 randomised trial. Proc Am Soc Clin Oncol 2001 ; 133 [abstract].
11. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers In node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8:1107-1116. (Pubitemid 34517647)
12. Moliterni A, Menard S, Valagussa P, et al. HER2 overexpression and doxorubicin In adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 2003; 21:458-462. (Pubitemid 46606475)
13. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers In primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil. J Clin Oncol 2005; 23:7483-7490. (Pubitemid 46291811)
14. Colozza M, Sidoni A, Mosconi AM, et al. HER2 overexpression as a predictive marker In a randomized trial comparing adjuvant cyclophosphamide /methotrexate/5-fluorouracil with epirubicin In patients with stage I/II breast cancer: long-term results. Clin Breast Cancer 2005; 6:253-259. (Pubitemid 47050802)
15. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354:2103-2111.
16. Petruzelka L, Pribylova O, Vedralova J, et al. C-erbB2 overexpression and treatment outcome In a randomized trial comparing adjuvant CMF and AC In equitoxic regiment In breast cancer. Proc Am Soc Clin Oncol 2000:534 [abstract].
17. Vera R, Albanell, Lirola JL, et al. HER2 overexpression as a predictor of survival In a trial comparing adjuvant FAC and CMF In breast cancer. Proc Am Soc Clin Oncol 1999:265 [abstract].
18. O'Malley F, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009; 101:644650.
19. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy In lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90:1346-1360.
20. Tanner M, Isola J, Wiklund T, et al. Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy In HER-2/neu-amplified breast cancer: Scandinavian Breast Cancer Group Trial 9401. J Clin Oncol 2006; 24:2428-2436.
21. Bartlett JMS, Munro AF, Cameron DA, et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines In the BR9601 adjuvant breast cancer chemotherapy trials. J Clin Oncol 2008; 26:5027-5035.
22. Paik S, Taniyama Y, Geyer C. Anthracyclines In the treatment of HER2negative breast cancer. [Editorial]. J Natl Cancer Inst 2008; 100:6-8.
23. Dhesy-Thind B, Pritchard KI, Messersmith H, et al. Her-2/neu In systemic therapy for women with breast cancer: a systemic review. Breast Cancer Res Treat 2008; 109:209-229. (Pubitemid 351644854)
24. Gennari A, Sormani MP, Pronzato P, et al. HER-2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100:14-20. (Pubitemid 351767337)
25. Slamon D, Elermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) In Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006:52 [abstract].
26. Harris LN, Yang L, Liotcheva V, et al. Induction of topoisomerase II activity after ErbB2 activation Is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7:1497-1504. (Pubitemid 32708611)
27. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival In patients with triple-negative breast cancer. J Clin One 2008; 26:1275-1281.
28. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Research 2007; 13:2329-2334. (Pubitemid 46698581)
29. Isaacs RJ, Davies SL, Sandi Ml, et al. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1998; 1400:121-137.
30. Goswami PC, Sheren J, Albee LD, et al. Cell cycle-coupled variation in topoisomerase II alpha mRNA Is regulated by the 3'-untranslated region. Possible role of redox sensitive protein binding In mRNA accumulation. J Biol Chem 2000; 275:3384-3392. (Pubitemid 32009162)
31. Durbecq V, Desmedt C, Paesmans M, et al. Correlation between topoisomerase-II alpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol 2004; 25:1473-1479.
32. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein In human breast tumor samples. Genes Chromosomes Cancer 2004; 39:288-297. (Pubitemid 38326310)
33. Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers In breast cancer with complementary use of array-CGH and tissue microarrays. J Pathol 2005; 205:388-396. (Pubitemid 40253928)
34. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy In advanced breast cancer. Br J Cancer 1998; 77:2267-2273. (Pubitemid 28263952)
35. Jarvinen TA, Kononen J, Pelto-Huikko M, Isola J. Expression of topoisomerase II alpha Is associated with rapid cell proliferation, aneuploidy, and c-erbB2 over expression In breast cancer. Am J Pathol 1996; 148:2073-2082. (Pubitemid 26170530)
36. Nakopoulou L, Lazaris AC, Kavantzas N, et al. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000; 68:137-143. (Pubitemid 32110322)
37. Di Leo A, Moretti E. Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. j Clin Oncol 2008; 31:5027-5035.
38. Harris LN, Broadwater G, Abu-Khalaf M, et al. Topoisomerase IIα amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy In HER2-amplified early breast cancer: Results of CALGB 8541/150013. J Clin Oncol 2009; 21:3430-3436.
39. Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. San Antonio Breast Cancer Symposium 2008:705 [abstract].
40. Mo YY, Beck WT. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines. Oncol Res 1997; 9:193-204.
41. Mirski SE, Bielawski JC, Cole SP. Identification of functional nuclear export sequences In human topoisomerase II alpha and beta. Biochem Biophys Res Commun 2003; 306:905-911. (Pubitemid 36776215)
42. Turner JG, Engel R, Derderian JA, et al. Human topoisomerase II alpha nuclear export Is mediated by two CRM-1 -dependent nuclear export signals. J Cell Sci 2004; 117:3061-3071. (Pubitemid 39117680)
43. Oloumi A, MacPhail SH, Johnston PJ, et al. Changes in subcellular distribution of topoisomerase II alpha correlate with etoposide resistance in multicell spheroid and xenograft tumours. Cancer Res 2000; 60:5747-5753. (Pubitemid 30808310)
44. Ernst Al, Soltermann A, Sigrist JA, et al. Ectopic expression of human topoisomerase II alpha fragments and etoposide resistance in mammalian cells. Int J Cancer 2000; 88:99-107.
45. Rimm DL, Barlow WE, Harigopal M, et al. Multiplexed AQUA based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessments. Proc Am Soc Clin Oncol 2009:704 [abstract].
46. Gustavson MD, Molinaro AM, Tedesch G, et al. AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma. Arch Pathol Lab Med 2008; 132:17461752.
47. Desmedt C, Azambuja E, Larsimont D, et al. Predicting the efficacy of anthracyclines In breast cancer (BC) patients: Results of the neoadjuvant TOP trial. Proc Am Soc Clin Oncol 2009:523 [abstract].
48. Orlando L, Del Curto B, Gandini S, et al. Topoisomerase II alpha gene status and prediction of pathological complete remission after anthrcycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positie breast cancer. Breast 2008; 17:506-511.
49. Slamon DJ, Mackey J, Robert N, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. San Antonio Breast Cancer Symposium 2007:13 [abstract].
50. Beser AR, Tuzlali S, Guzey D, et al. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 2007; 13:180-185.
51. Bofin AM, Ytterhus B, Hagmar BM. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003; 14:314-319. (Pubitemid 37521861)
52. Gennari A, Sormani M, Pfeffer U, et al. TOP mRNA expression in HER2 negative breast cancer. San Antonio Breast Cancer Symposium 2008:6036 [abstract].
53. McArthur HL, Tan LK, Patil S, et al. High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOP02 and HER2 coamplification is uncommon in human breast cancer. San Antonio Breast Cancer Symposium 2008:2023 [abstract].
54. Bartlett JMS, Munro A, Dunn JA, et al. Chromosome 17 polysomy (Ch17) as a predictor of anthraoycline response: emerging evidence form the UK NEAT adjuvant breast cancer trial. San Antonio Breast Cancer Symposium 2008:45 [abstract].
55. Järvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to the topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156:839-847. (Pubitemid 30626942)
56. Burgess D, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response In vitro and In vivo. Proc Natl Acad Sci U S A 2008; 105:9053-9058.
57. Potti A, Dressman H, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006; 12:1294-1300. (Pubitemid 44706932)
58. Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007; 8:1071-1078. (Pubitemid 350182953)
59. Reinholz MM, Bruzek AK, Visscher DW. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 2009; 10:267-277.
60. Arriola E, Marchio C, Tan D, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008; 88:491-503. (Pubitemid 351581454)
61. Hojilla CV, Wood GA, Khokha R. Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown In breast cancer. Breast Cancer Res 2008; 10:205.
62. González LO, Pidal I, Junquera S, et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer 2007; 97:957-963. (Pubitemid 47519308)
63. Lipton A, Ali SM, Leitzel K, et al. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 2007; 109:1933-1939. (Pubitemid 46744185)
64. Willemoe GL, Hertel PB, Bartels A, et al. Lack of TIMP-1 tumor cell immunoreactivity predicts effect of adjuvant anthraoycline based chemotherapy in patients (n 647) with primary breast cancer. San Antonio Breast Cancer Symposiom 2008:6042 [abstract].
65. Ejlertsen B, Jensen M-B, Nielsen KV, et al. TOP2A, TIMP-1 and responsiveness to adjuvant anthraoycline containing chemotherapy in high risk breast cancer patients. San Antonio Breast Cancer Symposium 2008:36 [abstract].
66. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14:518-527. (Pubitemid 351655218)
67. Farmer P, Bonnefoi H, Anderle P, et al. A stroma-related gene signature predicts response to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 1:68-74.